Publications by authors named "F Bellomo"

Background: Phelan-McDermid syndrome (PMS) is caused by monoallelic loss or inactivation at the SHANK3 gene, located in human chr 22q13.33, and is often associated with Autism Spectrum Disorder (ASD).

Objectives: To assess the clinical and developmental phenotype in a novel sample of PMS patients, including for the first time auxometric trajectories and serotonin blood levels.

View Article and Find Full Text PDF

In infantile nephropathic cystinosis, variants of the CTNS gene cause accumulation of cystine in lysosomes, causing progressive damage to most organs. Patients usually present before 1 year of age with signs of renal Fanconi syndrome. Cysteamine therapy allows cystine clearance from lysosomes and delays kidney damage but does not prevent progression to end-stage kidney disease, suggesting that pathways unrelated to cystine accumulation are also involved.

View Article and Find Full Text PDF

Key Points: Ketogenic diet can change the metabolism in the body and helped restore the function of altered pathways in nephropathic cystinosis. Ketogenic diet had significant benefits for preventing kidney damage, even when initiated after the onset of kidney impairment. Ketogenic diet may provide a partial therapeutic alternative in countries where cysteamine therapy is too expensive.

View Article and Find Full Text PDF

Introduction: The effectiveness of early interventions in young autistic children is well established, but there is great interindividual variability in treatment response. Predictors of response to naturalistic developmental behavioral interventions (NDBI), like the Early Start Denver Model (ESDM), are needed.

Methods: We conducted an exploratory study to prospectively seek predictors of response in 32 young children treated with ESDM after receiving an ASD diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • Cystinosis is a rare genetic disorder linked to mutations affecting the cystine transporter, leading to cystine accumulation in lysosomes; treatment includes cysteamine bitartrate, which helps reduce cystine levels.
  • Researchers developed a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to measure cysteamine levels in blood plasma, adhering to European Medicines Agency (EMA) guidelines.
  • The method was tested on samples from 8 cystinosis patients and demonstrated significant increases in cysteamine concentration post-treatment, providing a reliable tool for monitoring treatment effectiveness and supporting future pharmacokinetic studies.
View Article and Find Full Text PDF